Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Migraine Prophylaxis 2009 Dr Richard Peatfield. MD FRCP Princess Margaret Migraine Clinic Charing Cross Hospital London W6 8RF [email protected] Prevalence of headache in the previous year Rasmussen et al J. Clin.Epidemiol. 44 1147 1991 Age group n Migraine Men Women 387 353 Tension-type headache Men Women 387 353 25-34 35-44 45-54 55-64 All ages 5% 7% 6% 7% 6% 68% 63% 70% 49% 63% 18% 14% 12% 19% 15% 93% 92% 82% 74% 86% Functional impact of migraine by self-reported physician diagnosis of migraine. Lipton et al Headache 41 638 2001 INDICATIONS FOR MIGRAINE PROPHYLAXIS Two attacks monthly. Less frequent attacks proving intractable. Note Cost benefit. Abolition of the first hour or so of each headache if successful. Persistent symptoms after 2 hours, eg: Mild Headache Nausea Photophobia Disability Quality of life can be impaired despite ‘effective’ treatment. Migraine prophylactic medication Amine Modulation 1. b-blockers: Propranolol, Atenolol 2. 5-HT Blockers: Pizotifen, Methysergide 3. Tricyclics Channel Modulation 4. Anti-epileptics: Valproate, Topiramate 5. Calcium channel blockers: Flunarizine Others 6. Metabolic enhancers: Riboflavin, Nicotinamide 7. ACE Inhibitors: Lisinopril 8. Also: NSAID’s, Magnesium, Feverfew Prophylactic Agents: Europe v USA North America G5 EUROPE (France, Germany, Italy, Spain, and UK) Total others (26) propranolol 33% Propranolol 22% Amitriptyline 10% !0% Valproic acid 1% Amitriptyline 17% Nortriptyline 6% Other β-blockers Total others (33) 15% 7% Verapamil 8% Gabapentin 4% Valproate Topiramate 14% sodium 12% Other β-blockers 9% Pizotifen 17% Flunarizine 15% Source: IMS MIDAS; 2002 RXs; N2C Migraine Products + top products used for G43 diagnosis code (which includes off-label products). Migraine - Preventive Treatment First choice • betablockers • antiepileptic drugs Second choice • antidepressants • calcium-antagonists • serotonin antagonists Third choice • riboflavin, coenzyme Q10, magnesium “Special cases“ • menstrual migraine: • exercise induced: NSAIDs, continuous contraceptive pill, naratriptan, frovatriptan betablockers, indomethacin Sandor 2004 Conventional migraine prophylactic drugs Daily dose (adult) mg. Propranolol Atenolol Pizotifen Methysergide Valproate Naproxen Amitriptyline Start Max. 80 50 0.5 1 400 250 10-25 320 150 1.5 6 1600 1000 100 b Blockers Diener Mode of action unknown; no animal models No proper dose finding studies of propranolol 160=80mg, or 160>80? Short titration times, never over 12 weeks Metoprolol second greatest number of trials, again for a short time Bisoprolol largest, best designed trial 226 patients. All seem of equal efficacy ~ 50% response rate. No correlation between plasma levels and efficacy 16 comparative trials Metoprolol > aspirin Propranolol > Nifedipine Neither trial with placebo Flunarizine = Propranolol [Cephalalgia 2001] b Blockers Diener Propranolol since 1964; very cheap 26 drugs now available:- Effective Perhaps not Propranolol Metoprolol Timolol Bisoprolol Nadolol Atenolol Acebutolol Alprenolol Oxprenolol Pindolol ?? Differences due to trial design Propranolol http://www.cochrane.org/reviews/en/ab003225.html Antidepressants Bendtsen Migraine Widely used – second only to b-blockers. No DBXO trials following IHS guidelines Three small trials of amitriptyline 1973-1987 21-42% reduction in attacks Effect independent of depressive state Trials of fluoxetine- benefit modest if any Tension-type headache Most trials of amitriptyline (1964-1996) show benefit Pfaffenrath’s trial had a tough endpoint Bendtsen’s own trial:- (1996) Amitriptyline effective; Citalopram had no effect Holroyd 2001 144 patients 30% reduction Antidepressants Discordant results with SSRI’s:- Patients do not care any more Headache continues unaltered Not evidence based!! Valproate in Migraine Prevention: Efficacy—ITT 45 * 38 40 * 42 * 36 35 Mean 30 Reduction 25 in 4-Week Migraine 20 Frequency15 (%) 10 8 5 0 Placebo 500 mg 1000 mg 1500 mg *P<.05. Valproate ITT=intent to treat. Klapper J and the Divalproex Sodium in Migraine Prophylaxis Study Group. Cephalalgia. 1997;17:103-108. Valproate in Migraine Prevention: Overall Responder Rate—ITT 60 * 50 44 40 ≥50% Responder 30 Rate (%) 21 20 10 0 Placebo Valproate (vs placebo). ITT=intent to treat. Klapper J and the Divalproex Sodium in Migraine Prophylaxis Study Group. Cephalalgia. 1997;17:103-108. *P≤.05 Divalproex in Migraine. Cochrane reviews 2006 http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003226/frame.html Methysergide • 5HT2 A,B&C receptor antagonist (But mianserin, ketanserin and ICI 169369 do not work) • Metabolised to Methylergometrine, an agonist at 5HT1 B receptors. - Greater bioavailability - Longer half-life. • Antagonist at 5HT7 receptors. • Increases Neuropeptide Y levels in the hypothalamus – appetite stimulant Methysergide in Migraine Prophylaxis 60 patients, double blind cross over. 6 mg daily. Placebo No attacks Over 50% fewer Unchanged 4 12 44 Methysergide 16 18 26 p<0.01 Petersen & Moller: Clin.Pharm.Ther. 1966 7 520. Methysergide: side effects Less severe than the publicity! Pain in the legs (?vasospasm) is less likely if the drug dose is increased slowly ( 0.5mg daily for a few days- etc etc). Retroperitoneal and cardiac fibrosis. Rare; commoner with larger doses. In one series 11/19 affected patients had received > 8mg/day Seen after 6mg/day or less. Reversible if the drug is stopped. The risk of retroperitoneal fibrosis is lessened if the drug is stopped for 1 month every 6 months. Methysergide: fibrotic side effects Continuous use ( ?Dose) Stopping for 1 month annually n 1000 cases 36 300 Nil (Bala Am Ht J 1974 88 640) Worth regular auscultation, and checking a renal ultrasound and echocardiogram annually What to do in the ‘Holidays’? • Topiramate • Prednisolone ( 50mg, reducing by 5mg/day) Topiramate in Migraine Prevention Response to Topiramate Therapy (50% Responder Rate) 60 MIGR-001 MIGR-002 50 % of patients with >50% reduction in Migraine Frequency 40 30 54‡ 49 36* 23 ‡ 52‡ 47‡ 39† 23 20 10 0 Placebo 50 mg/d 100 mg/d 200 mg/d Topiramate *P<.05; †P<.01; ‡P<.001. Mathew N et al. Neurology. 2003;60(suppl 1):A336; Brandes JL. et al. JAMA. 2004;291(8):965-973 MIGR-001 / MIGR-002 Topiramate in Migraine Prevention: Onset of Action Month 0 1 2 3 4 5 6 0.0 -0.5 Cumulative Reduction in -1.0 Mean Migraine -1.5 Frequency -2.0 * † † † † ‡ ‡ ‡ ‡ † ‡ † ‡ -2.5 Placebo (n=115) Topiramate 100 mg/d (n=125) Topiramate 50 mg/d (n=117) Topiramate 200 mg/d (n=112) *P=.032; †P≤.015; ‡P<.001. Mathew N et al. Neurology. 2003;60(suppl 1):A336; Brandes JL. et al. JAMA. 2004;29198):965-973 Topiramate in Migraine. Cochrane reviews 2006 http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003226/frame.html Topiramate side-effects 50% get paraesthesiae – carbonic anhydrase inhibition - try K+ 20% Cognitive – concentration, memory, speech unpredictable ? K+ 1½% Kidney stones Calcium oxalate Fatigue Anorexia; weight loss Diarrhoea Taste change Glaucoma Brandes JAMA 2004 291 965; Silberstein Arch N. 2004 61 490 ‘Therapeutic gain’ compared to placebo proportion of patients with 50% reduction in attack frequency (verum – placebo) valproate 45 betablockers 40 amitriptyline therapeutic gain 20 Mg (24 mM) 18 riboflavin (Vit B2) 37 33 coenzyme Q10 gabapentin 22 topiramate 40 flunarizine 1st choice (EBM) 0 42 5 10 15 20 25 30 well tolerated substances, mechanism: energy metabolism new antiepileptics 35 40 45 50 [Sandor 2004] 55 Levetiracetam in Headache Co-sponsored prospective multicentre trial of 1.5G - No benefit. Unpublished. ?? Suppressed (? Dose too low) Young (Philadelphia) Open study 3G 35% >50% reduction in attacks No control series Personality change problems Headache 2004 44 2238 Clin J Pain 2004 20 198 All retrospective Angiotensin :Converting enzyme inhibitors and receptor antagonists Lisinopril 20mg is an effective prophylactic 20% improvement above placebo in a DBXO trial in 47 patients [Schrader BMJ 2001 322 19-22]. Fewer headaches in patients on ACE inhibitors [Etminan Am J Med 2002 112 642-6] Candesartan Trial of 16mg daily in 57 migraine patients 32-46% had headache reduced by 50% No significant adverse events [Tronvik. JAMA 2003 289 65-9]. Tronvik. JAMA 2003 289 65-9 Binding of 5-HT2B receptors Botulinum Toxin Zinc dependent Metalloproteinases Cleaves proteins responsible for exocytosis of transmitter vesicles Acts on sensory afferents too Inhibits release of all neurotransmitters, including SP, CGRP etc, in doses comparable to those used in man. Consensus is that is does work, so long as there are enough separate injection sites – 15-20 per patient. Sites of action are not confined to the neuromuscular junction In published trials most patients are unaware of the treatment used. Some trials are biased; placebo patients less severe. Type A – Most potent and lasting effect Light Chain cleaves SNAP 25 protein inside membrane - 1 of the 3 proteins in SNARE complex that leads to Ach release Collateral axonal sprouts lead to early recovery, until original terminal recovers Sensory effects of botulinum toxin In cervical dystonia low doses relieve pain before the motor effects Relja 2006 Suppresses secondary inflammatory pain after formalin injection Release of Substance P, CGRP, etc. Cui Pain 107 125 2004 Less c-fos expression in cervical neurones Gazer~~ Pain 122 315 2006 Botulinum Toxin in Chronic Daily Headache Mathew Headache 45 293 2005. 355 subjects 47% met criteria for analgesic abuse; slightly more in the active group Side effects in 2.3% only (usually neck pain from weakness) Primary end-point (change in the number of headache free days) not met --6.7 cf 5.2.in placebo non-responders Doubtful clinical significance Significant improvement in:Headache frequency The proportion with >50% decrease of headache days per month Those not on prophylaxis [H 45 315 2005] Botulinum Toxin NO effect in tension-type headache Possible effect in Migraine High Placebo response rates Greatest potential role in ‘Chronic Migraine’ Blinding Aesthetic change Less Sweating Incidental effect in cosmetic patients In the trials the number of patients guessing correctly fell from 65% to 55% as they improved! Exploding vs Imploding Headaches Burstein Kyoto, Dodick AAN 2006 Exploding Bursting 12% responded Imploding Tightening 92% responded Ocular 100% responded ? Related to fine extracranial c-fibres passing through the skull to innervate the dura (in the rat) Differences in Migraine Features for Botulinum Toxin-A Responders and Nonresponders Responders 100 Non-responders 92 89 90 88 80 71 52 60 40 20 2.5 0 0 100 % of study participants % improvement over pre-treatment phase Responders Non-responders 80 70 60 50 40 30 20 10 -2 8 11 0 -20 Frequency Duration Pain Severity Headache Characteristics N=35 responders N=24 nonresponders Exploding Imploding Description of Headache Pain Burstein et al., Neurology 2006 Expensive! £129 for a 100 unit ampoule 4 patients at low dose – 25 units per patient Trial used 150-190 units per patient USA different from UK! Vertical integration of costs and savings in the USA Chronic migraine sufferers are already costing insurers a lot of money by the time they are referred for Botox treatment, and the additional costs are seen as marginal and the potential gains large. If you don’t have Botox… USA UK Emergency $600 Multiple Opinions Someone Analgesics Scans Else’s Cost of Botox Budget! Prophylaxis in real life MIGRAINE PROPHYLACTIC MEDICATION Dose used in trials Propranolol Atenolol Pizotifen Methysergide Valproate Amitriptyline Topiramate Cost / 28 days mg £ 240 100 3 6 1000 c100 100 1.44 0.95 8.28 37.68 7.84 2.41 32.07 Percent of patiens likely to make a 50% improvement compared to placebo 34 33 28 30 34 32 31 Revised prices 27 November 2005 Consensus view on migraine prophylaxis Offered :- Patients with 6 or more headache days per month; 4 or more days with some impairment; or 3 or more days with severe impairment. Considered:- Patients with 4 or 5 headache days per month with normal functioning; 3 days with some impairment; or 2 days with severe impairment. Not indicated:- Patients with <4 headache days per month with normal functioning; or no more than 1 day per month regardless of impairment. Lipton Neurology 2007 68 343 Principles of Preventative Pharmacotherapy Goadsby Clarify Diagnosis:- History is taken, not given. Explain what it means to the patient. Assess the burden to the patient. Establish what the patient expects. Be clear what the Physician can offer; limited! Advise on areas where the patient can intervene. Optimise the treatment of acute attacks. Plan preventative treatment. Migraine: Prophylactic trials Small trials in single centres Some crossover and some parallel group designs Variety of endpoints used:- Percentage of patients improving in categories - Overall percentage improvement Not a comprehensive metaanalysis:results from individual selected trials. DRUGS ACTING ON SEROTONIN RECEPTORS (Adapted from Saxena) Sumatriptan 5HTID Agonist Pizotifen Methysergide Ergotamine Inactive Agonist 5HT2A Inactive Partial Agonist Antagonist Antagonist 5HT2C Inactive 5HT3 Inactive Antagonist Antagonist Inactive Inactive Agonist Inactive Agonist Select for positive side effects, e.g. • anxiety → betablocker • insomnia → sedating tricyclic at night (amitriptyline) • constipation → magnesium • obesity → topiramate • comorbid depression → antidepressant in sufficient dosage Sandor 2004 Long Q-T interval Upper limit 450msec, less in women Long QT interval Measure from the beginning of Q to the end of T Resting ECG can be normal –need an exercise test Patients may collapse during exercise QTc is corrected for the heart rate >460msec in women; 440msec in men Congenital long Q-T interval • 7 identified genes; 300 mutations • Mostly related to K+ Channels • Risk of sudden death, especially during sudden arousal or exercise • Prophylactic b-blockers may lower this risk Drugs prolonging the Q-T interval Withdrawn Terfenadine, Astemazole, Cisapride. Hazardous Amiodarone, Sotalol. Quinidine Care! Erythromycin, Chlorpromazine, Haloperidol, Tricyclics, Domperidone, Amantadine. www.longqt.org Valproate in Migraine Prevention • 16-week double-blind, placebo-controlled trial of valproate; N=171 • Study design – 4-week placebo run-in – Patients randomized to receive 500, 1000, or 1500 mg/d valproate or placebo for 12 weeks • Initial dose, 250 mg/d • Titration every 4 d (8 d for 500 mg/d group) of 250 mg/d to maintenance dose • 8-week maintenance phase – Efficacy evaluations every 4 weeks Klapper J et al. Cephalagia. 1997;17:103-108. Topiramate in Migraine Prevention 75% and 95% Responder Rate 30 6% 25 6% 20 % of Patients 6% 6% 17% 17% 15 24% 10 19% >95% 75%-94% Reduction 5 0 Topiramate 100 mg/d (MIGR-001) Topiramate 100 mg/d (MIGR-002) Topiramate 100 mg/d (MIGR-003) Propranolol 160 mg/d (MIGR-003) Mathew N et al. Neurology. 2003;60(suppl 1):A336; Brandes JL et al. JAMA. 2004;291(8):965-973 MIGR-001 / MIGR-002 / MIGR-003